title: [Type III procollagen N-peptide and hyaluronate in serum and dialysate of CAPD patients].
abstract: Long-term CAPD may develop peritoneal fibrosis, which is thought to be related to permanent loss of ultrafiltration capacity and sclerosing peritonitis. In CAPD patients, we examined the serum (P-) and effluent (D-) levels of type III procollagen N-peptide (P III P) and hyaluronate (HA), which are expected to change concomitantly with a local increase in submesothelial extracellular matrix of the peritoneum. We selected 40 CAPD patients (age: 46.3 +/- 11.3 years, time on CAPD: 33.6 +/- 26.2 months), who were not suffering from chronic liver disease, any inflammatory disease, nor peritonitis during the previous month. P-P III P, P-HA, D-P III P, and D-HA were measured by PET (values after 4-hour dwelling). D/P ratios (P III P 0.330 +/- 0.137, HA 5.68 +/- 6.44) suggested that their source was from the peritoneum. Although neither P-P III P nor log P-HA value had a significant correlation with age nor time on CAPD, both had significantly positive correlations (p = 0.0009, 0.0005, respectively) with time on total dialysis (including hemodialysis). D-P III P did not have a significant correlation with age nor time on total dialysis but had a significantly positive correlation (p = 0.0098) with D/P-creatinine. Although log D-HA had significantly positive correlations with time on CAPD and time on total dialysis (p = 0.0007, 0.0051, respectively), time on CAPD was first entered (F = 16.5) and time on total dialysis was removed (F to enter: 4) by stepwise regression analysis. In conclusion, a local increase in extracellular matrix of the peritoneum in CAPD patients, indicated by increases in P III P and HA in the effluent, may be related to higher peritoneal permeability and a longer duration of PD.
authors.affiliation: Department of Internal Medicine, Sakura National Hospital, Chiba, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Wakabayashi
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: Y
authors.initials: Y
authors.lastname: Miura
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: M
authors.initials: M
authors.lastname: Nishimura
authors.forename: H
authors.initials: H
authors.lastname: Tsuchida
authors.forename: T
authors.initials: T
authors.lastname: Shigematsu
authors.forename: Y
authors.initials: Y
authors.lastname: Kawaguchi
authors.forename: O
authors.initials: O
authors.lastname: Sakai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015314:Dialysis Solutions / Q000737:chemistry*; D005109:Extracellular Matrix / Q000378:metabolism; D005260:Female; D005355:Fibrosis / Q000209:etiology; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010537:Peritoneum / Q000378:metabolism / Q000473:pathology*; D011347:Procollagen / Q000097:blood*; D013997:Time Factors
chemical_list: D015314:Dialysis Solutions; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D006820:Hyaluronic Acid